Ephedrine case: Narcotics court indicts PML-N's Hanif Abbasi, 7 others

Abbasi denies charges, says case is based on ill-intent


Web Desk October 29, 2014
Ephedrine case: Narcotics court indicts PML-N's Hanif Abbasi, 7 others

RAWALPINDI: A Control of Narcotics Substances (CNS) court on Wednesday indicted former MNA of Pakistan Muslim League - Nawaz Hanif Abbasi and seven others in the ephedrine case today, Express News reported.

Hanif Abbasi was accused of misappropriating 500kg of the controlled chemical ephedrine, obtained in 2010, and allegedly selling it to narcotics smugglers.

During the hearing today, Judge Akhtar Bahadur issued notices to all the witnesses in the case and asked them to appear for the next hearing on November 12.

Abbasi denied these charges and said the case was based on ill-intent.

Earlier, the court had deferred the indictment of these accused as one of them was away to perform Hajj.

Anti-Narcotics Force (ANF) had submitted a challan in the CNS court in the past and declared Abbasi, his brother and five employees of Grey Pharmaceuticals as accused.

COMMENTS (10)

Khalid | 10 years ago | Reply

Our courts cannot punish Gullu Butt let alone these big smugglers. People with such character are always in high demand and enjoy full support of political parties. No use wasting public money on useless trials and they should be freed on first hearing. Mr. Abbasi, your hostile and ludicrous comments on various individuals have been most distasteful on TV news programs. Indeed “what goes around comes around”.

Sodomite | 10 years ago | Reply

@YP Mississauga: For this very reason I don't watch TV talk shows. Same felons belonging to one or the other political parties exploits connections with officialdom to rip-off the Pakistani state. Then the Judiciary moves into overdrive to absolve such criminals for their own pecuniary benefits. And so the circus goes on.

VIEW MORE COMMENTS
Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ